Background/Aims: This study aimed to pathologically elucidate the roles of interleukin-12 receptor (IL-12R) β2 and interleukin-23 receptor (IL-23R) expression in tumor cells and tumorinfiltrating lymphocytes (TILs) in the tumor microenvironment and to determine their combined effect on prognosis of laryngeal cancer (LC). Methods:The tumor-cell expression scores and TIL positivity ratiosof IL-12Rβ2 and IL-23R in matched LC and normal laryngeal tissue samples from 61 LC patients were measured via immunohistochemistry (IHC). We adopted a linear regression model to analyze the correlation between IL-12Rβ2 and IL-23R expression in tumor cells and TIL ratios. TheKaplan-Meier log-rank test and Cox regression hazard ratios were used to analyze survival. Results: LC tumor cells had a higher IL-12Rβ2 expression and TIL ratio than IL-23R expression and TIL ratio. The significant correlations between IL-12Rβ2 and IL-23R expression and TIL ratios were identified in LC tissues, particularly in well-differentiated LC. Furthermore, either high tumor cell IL-12Rβ2 or low IL-23R expression had better survival than its corresponding low or high expression, respectively. Similar results did for IL-12Rβ2 ratio and IL-23R ratio. Finally, patients with both high IL-12Rβ2 and low IL-23R had the best prognosis among any other combined groups with both gene expression (HR, 0.1; 95% CI,
Introduction
In the United States, approximately 9, 500 patients are diagnosed every year with laryngeal cancer (LC) [1] , and an estimated 26, 400 new laryngeal cancer cases and 14, 500 cancer deaths occurred in China in 2015 [2] . Tobacco carcinogens are the major risk factors and cause genetic and epigenetic damage in epithelial cells [3] . The accumulation of genetic aberrations and damage facilitates the epithelial-mesenchymal transition (EMT), in which cancer stem cells (CSCs) are thought to be the oncogenic derivatives of normal-tissue stem or progenitor cells in primary tumors at a very early stage of development [4] .
When EMT has occurred and intrinsic tumor-suppressor mechanisms have failed, CSCs experience extrinsic pressure from tumor-infiltrating lymphocytes (TILs) [5, 6] . The various laryngeal TILs interact with secreted cytokines in the tumor microenvironment and typically either kill tumors at early stages or promote tumors at advanced stages. Therefore, CSCs and TILs can form the 'three-E' sequential cancer immunoediting phases: elimination, equilibrium, and escape [5] [6] [7] [8] .
The equilibrium phase is mainly based on adaptive immunity through the CD4 + T helper (Th)1/Th2 cell paradigm [5, 7] . Th1 cells and their product interferon (IFN)-γ are essential to maintain tumor cells in a state of functional dormancy, whereas Th2 cells stimulate CD4 + Tregs to block the anti-tumor activity of CD4 + Th1 and CD8 + CTL cells [9] [10] [11] . Moreover, in maintaining occult cancer cells in a state of immune-mediated dormancy, the opposing and critical roles of interleukin (IL)-12 and IL-23 have been identified in methylcholanthrene (MCA)-induced cancers [12] .
IL-12 and IL-23 are related in structure, but distinct in function in maintaining immune equilibrium [12, 13] . Structurally, IL-12 and IL-23 are heterodimeric cytokines that share a subunit, IL-12p40, and bind to a common receptor chain, IL-12 receptor (IL-12R)β1 [14] . The IL-12R consists of IL-12Rβ1 and IL-12Rβ2, while IL-23 binds to a receptor composed of IL-12Rβ1 and IL-23R [14] . Functionally, the IL-12/IL-12R axis promotes the differentiation of naive CD4 + T cells into IFN-γ-producing TH1 cells, whereas IL-23/IL-23R promotes the Th17 and Treg cell lineages. Th1 and Th17 productions are critical for maintaining immunity equilibrium, and therefore, Th17 and Treg dysregulation can lead to many autoimmune diseases [14] [15] [16] [17] .
In the tumor microenvironment, opposing roles on carcinogenesis have been identified for IL-12 and IL-23 [12, 13] . In ovarian cancer, large quantities of CD8 + TILs and a high CD8+/ Treg cell ratio indicate favorable prognosis [18] . IL-12 can facilitate the tumor infiltration of CD8 + T cells, whereas IL-23 can reduce CD8 + T cells and promote Treg cells in the tumor, thereby enhancing tumor angiogenesis [13] . Furthermore, the IL-12 and IL-23 equilibrium can be disrupted by the over-activation of the transcription factor STAT3 [13, 19] . In tumorinfiltrating CD4
+

Foxp3
+ T-regs, overactive STAT3 significantly upregulates IL-23R, and the IL23-driven IL-23R-STAT3 pathway can form a positive-feedback loop, thereby facilitating tumor growth [13, 20, 21] . Moreover, IL-23R blockade significantly reduces tumor growth in vivo [13, 20] . In addition, overactive STAT3 can decrease IL-12 transcription and thereby reduce INF-γ production [22] , which in turn, can reduce IL-12Rβ2 expression in human peripheral blood mononuclear cells (PBMCs) [23] .
Likewise, opposing impacts on prognosis have been identified for IL-12Rβ2 and IL-23R expression in many tumor types. Patients with high IL-12Rβ2 expression in colorectal [24] , lung [25] , and oral squamous cell [26] cancers have prolonged disease-free survival, whilepoor prognosis and promotion of tumor growth are associated with high IL-23R [27] , colorectal [28, 29] , and oral [30] cancer cells. Furthermore, IL-12Rβ2 is expressed significantly more frequently in stage-I tumors than in stage-II or -III tumors, suggesting that IL-12Rβ2 downregulation is a tumor-escape mechanism [25] . In contrast, IL-23R is expressed in squamous cell carcinoma and non-small cell lung cancer cell lines via alternative splicing [31] , and spliced isoforms of IL-23R can affect cancer cell response to IL-23 [32] , which may promote tumor growth [33] .
In these previous studies,opposing roles of IL-12Rβ2 and IL-23R were identified not only with regard to their tumor cell expression but also regarding their TIL ratios. Recently, we demonstrated that a high ratio of IL-12Rβ2 + TILs (≥0.35) in LC indicates a favorable prognosis [34] , while a poor prognosis is potentially associated with a high ratio of IL-23R + TILs (unpublished data). Therefore, we hypothesized that IL-12Rβ2 and IL-23R may construct an immunological equilibrium within the tumor cells and TILs, respectively. Furthermore, this equilibrium may be associated with tumor cell differentiation, which may further modulate the tumor cell tumorigenicity and impact TILs within the tumor microenvironment, leading to divergent prognoses. These results may further help us to understand and stratify immunological parameters and provide a strong prognostic indicator.
Materials and Methods
Patients and tissue samples
All patients provided written informed consent for use of their tissue samples and information, and this study was approved by the institutional review board at the Anhui Medical University. After the clinical records of LC patients in a database at our institution were reviewed, 61 patients who underwent surgery with pathologically confirmed LC from 2008 to 2016 were enrolled. A consort flow diagram is presented in Fig. 1 , in which the selection criteria and the eligibility assessment were executed. The patients had archived tumor samples and available data for a minimum follow-up of 36 months or until death. Tumor histological classification and differentiation grades were determined based on the 1999 World Health Organization histological classification standards for LC. Tumor staging was performed using the 2009 TNM staging criteria of the Union for International Cancer Control. According to the study protocol, posttreatment follow-up for all patients consisted of medical record monitoring and/or telephone interviews, and clinicopathological data were collected for all 61 patients (Table 1) .
All tumor samples from the 61 patients contained more than 50% tumor cells and were stored at -80°C until use. Paired LC and adjacent normal mucous membrane tissue samples were obtained. Adjacent normal tissue samples were obtained at least 5 mm from the tumor margins [35] . All 61 paired samples were used for IL-12Rβ2 and IL-23R expression assessment using immunohistochemistry (IHC).
Pathological review
Hematoxylin and eosin-stained slides containing paired frozen tumor and normal tissue sections were examined twice by pathologists to ensure that tumor samples with high-density cancer foci (>75%) were used and that the normal tissue had no tumor components. All samples were independently reviewed by two pathologists, and disagreements were settled via discussion. Immunohistochemical staining for IL-12Rβ2 andIL-23R IHC studies were performed using a streptavidin-biotin-peroxidase complex-based method [36] . Five-micrometer, formalin-fixed, paraffin-embedded tissue sections were deparaffinized in xylene and rehydrated with gradient concentrations of ethanol. Endogenous peroxidase activity in the pathological sections was blocked with 0.35% H 2 O 2 in phosphate-buffered saline. Antigens were retrieved by heating the sections in a 350-W scientific microwave for 5 minutes, and nonspecific binding in the sectionswas blocked with 1% bovine serum albumin in phosphate-buffered saline. Sections were stained with anti-IL23Rantibody (Abcam, Eugene, Oregon, U.S.) or anti-IL-12Rβ2 antibody (Abcam, Eugene, Oregon, U.S.) at a 1:500 dilution and visualized with a secondary antibody (EnVision; DakoCytomation, Glostrup, Denmark). The slides were then incubated with 3, 3'-diaminobenzidine chromogen (DakoCytomation), counterstained with Mayer's hematoxylin, and mounted with Aquatex (Merck, Darmstadt, Germany).
Immunohistochemical staining intensity and immunoreactive score assessment Scoring of IHC staining intensity was performed according to the immunoreactive score (IRS) assessment [37, 38] , which is a standardized protocol for the semiquantitative measurement of the expression of IHC markers on a wide spectrum. The IRS ranges from 0 to 12 as a product of multiplication of the positive-cell proportion score (0-4) and staining intensity score (0-3) ( Table 2) .Using this method, the IRS was calculated for IL-12Rβ2 or IL-23R expression in LC samples.
TIL assessment and IL-12Rβ2-or IL-23R-positive TIL ratio calculation
Using the method of TIL assessment described in a previous breast cancer study [39] , the following criteria were used for the TIL calculation: 1) lymphocytes were counted in the highest lymphocyte-enriched areas in 10 consecutive high-power microscopic fields (magnification, 40×; field diameter, 490 mm), and the results were averaged; 2) theIL-12Rβ2 + or IL-23R + TIL ratio was calculated by dividing the number of IL-12Rβ2 + or IL-23R + TILs, respectively, by the total number of TILs; 3) the TILs within the borders of invasive tumors were evaluated; 4) the TILs in tumor zones with crush artifacts, necrosis, or regressive hyalinization as well as in previously obtained core biopsy sites were excluded from the final calculation; 5) all mononuclear cells (including lymphocytes and plasma cells) were scored, but polymorphonuclear leukocytes were not; 6) one section of sample tissue (4-5 mm; magnification, 200-400×) per patient was considered to be sufficient for analysis; and 7) a pathologist fully assessed the average density of TILs in the tumor area without focusing on hot spots. For cut-off values, we adopted the median of ratio of IL-12Rβ2 + and IL-23R + lymphocytes in adjacent normal tissues (Table 3) .
Statistical analyses
The data are expressed as the mean ± standard deviation. In tissue samples, clinicopathological characteristics and IL-12Rβ2 and/or IL-23R expression were analyzed using the χ 2 test. Differences in variables within groups (overall cases group; well-differentiated [WD] group;moderately and poorly differentiated [MPD] group) were compared using paired Student t-test. We adopted a linear regression model to analyze the correlation between IL-12Rβ2 and IL-23R tumor cell expression and TIL ratios. The Kaplan-Meier log-rank test and Cox regression models were used to estimate overall survival in the 61 patients grouped for joint effects. Two-sided p values less than 0.05 were considered significant. The data were analyzed using the SPSS 20.0 statistical software program (version 20.0; IBM Corporation, Armonk, NY, USA).
To group tumors based on IL-12Rβ2 or IL-23R expression, consistent with a previous study, we used the median IRS value (tumor cell expression) as the cut-off value to separate the 61 patients into the lowand high-expression groups. With these cut-off values, we separated the 61 patients into IL-12Rβ2 low-(IRS<6, n=22) and high-(IRS≥6, n=39) expression groups and into IL-23R low-(IRS<4, n=40) and high-(IRS≥4, n=21) expression groups.
To group tumors based on IL-12Rβ2 + or IL-23R + TIL ratios, consistent with a previous study, we used the median ratio of IL-12Rβ2 + (35%) or IL-23R + lymphocytes (30%) in adjacent normal tissues as the cutoff value. Using these cut-off values, we separated the 61 patients into IL-12Rβ2 + high-(ratio≥35%, n=24) and low-(ratio<35%, n=37) ratio groups and IL-23R + high-(ratio ≥30%, n=36) and low-(ratio <30%, n=25) ratio groups.
To evaluate joint effects of IL-12Rβ2 and IL-23R tumor cell expression, according to the respective anti-tumor and pro-tumor roles of IL-12Rβ2 and IL-23, we separated the 61 patients into 3 groups as follows: patients with high IL-12Rβ2 expression and low IL-23R expression (n=21); patients with both high or both low IL-12Rβ2 and IL-23R expression (n=34); and patients with low IL-12Rβ2 expression and high IL-23R expression (n=6). Likewise, to evaluate the joint effects of the IL-12Rβ2 + and IL-23R + TIL ratios, we separated the 61 patients into 3 groups as follows: patients with a high IL-12Rβ2 + ratio and low IL-23R ratio (n=20); patients with high or low ratios of both IL-12Rβ2 + and IL-23R + TILs (n=26); and patients with low IL-12Rβ2 + ratios and high IL-23R + ratios (n=15). 
Results
Pathological characteristics of TIL ratios of IL-12Rβ2 and IL-23R in tumors
In theIHC analysis, IL-12Rβ2 and IL-23Rimmunostaining was present at mild, moderate and strong intensities that variedin differenttumor cells. Furthermore, the density and quantity of IL-12Rβ2 + and IL-23R + TILsvaried depending on the area (intra-tumor or peripheral-tumor), peripheral necrosis and infective inflammation, while the ratios of IL-12Rβ2 + and IL-23R + TILs remained relatively steady. In LC, WD tumors consistently + TILs on the most adjacent embedded pathology section. Furthermore, tumors that were moderately differentiated (MD) consistently had reduced IL-12Rβ2 immunostainingintensity and decreased levels of IL-12Rβ2 + TILs, but increased IL-23R immunostaining intensity and increased levels of IL-23R + TILs. Moreover, poorly differentiated (PD) tumors had variable (mild, moderate and strong) intensities of IL-12Rβ2-and IL-23R-immunostaining, with dynamic, changing quantities and ratios of IL-12Rβ2 + and IL-23R + TILs (Fig. 2) . Taken together, we found that tumor cell differentiation potentially correlated with the (tumor cell) expression of IL-12Rβ2 and IL-23R and the ratios of IL-12Rβ2 + and IL-23R + TILs. Therefore, we further compared and analyzed the correlation between IL-12Rβ2 and IL-23R tumor cell expression and the ratios of positive TILs. Demographic characteristics by group are presented in Table 4 .
Expression differences of IL-12Rβ2 and IL-23R in tumors and their correlations with tumor cell differentiation
Overall, among the 61 cancer tissues, we found that IL-12Rβ2 expression was higher than that of IL-23R (Fig. 3A-1) . Furthermore, when stratified by tumor cell differentiation (WD and MPD), we found that the expression difference was more predominant in WD cancer tissues (Fig. 3A-2) , whereas no significant difference was found in the MPD cancer tissues (Fig. 3A-3) . Likewise, linear regression analysis found that IL-12Rβ2 expression correlated with IL-23R expression in the overall sample of 61 cancer tissues (Fig. 3B-1) . Moreover, when stratified by tumor cell differentiation (WD and MPD), we found that linear regression significance was more prominent in WD cancer tissues (Fig. 3B-2) , whereas there was no significant difference in MPD cancer tissues (Fig. 3B-3 ). Taken together, opposing roles of IL-12Rβ2 and IL-23R expression had expressive correlation, which created an equilibrium within the tumor cells. Furthermore, WD tumors achieved that equilibrium and were associated with favorable prognosis, while MPD tumors did not achieve that equilibrium and were associated with unfavorable prognosis. 
IL-12Rβ2 + and IL-23R + TIL ratio differences in tumors and correlations with tumor cell differentiation
In the total sample of 61 cancer tissues, we found that IL-12Rβ2 + TIL ratios were higher than the IL-23R + TIL ratios (Fig. 4A-1) . Furthermore, when stratified by tumor cell differentiation (WD and MPD), we found that the significance of the difference in ratios of IL-12Rβ2 + and IL-23R + TILs was more prominent in WD cancer tissues ( Fig. 4A-2 ), whereas no significant difference was found in MPD cancer tissues (Fig. 4A-3) . However, no significant linear correlation was found between the ratios of IL-12Rβ2 + and IL-23R + TILs ( Fig. 4B-1 ; 4B-2; 4B-3). TILs or of both low and both highIL-12Rβ2 and IL-23RTILs (log rank, p=0.012; Fig. 5B ).
Multivariable analysis of combined expression of IL-12Rβ2 and IL-23R on prognosis
Multivariable analysis indicated a significant association between joint tumor cell expression (IL-12Rβ2 low and IL-23R high ) and overall survival (hazard ratio, 0.1; 95% confidence interval, 0.0-0.8, Table 5 ). Likewise, a significant association between joint TIL ratio (IL-12Rβ2 low and IL-23R high ) and overall survival (hazard ratio, 0.1; 95% confidence interval, 0.0-0.4) was also identified (Table 6) . high and IL-23R low expression (n=21) had a higher survival rate than patients with IL-12Rβ2 low and IL-23R high (n=6) and patients with IL-12Rβ2 and IL-23Rexpression that was both low and both high (n=34).
(B) Patients with IL-12Rβ2
high and IL-23R low TILs ratios (n=20) had a higher survival rate than patients with IL-12Rβ2 low and IL-23R high TIL ratios (n=15) and patients with IL-12Rβ2 and IL-23RTIL ratios that were both low and both high (n=26). Table 6 . OS analysis on IL-12Rβ2/IL-23R TIL ratio in LC patients (N=61) 
Discussion
In the LC tumor microenvironment, IL-12Rβ2 and IL-23R are two closely related receptors that participate via critical but opposing roles in tumor immunity [13] [14] [15] . In this study with 61 LC cases, we evaluated their combined roles by assessing tumor cell expression and calculating TIL positivity ratios. We found that LC tumor cells had higher IL-12Rβ2 expression than IL-23R expression. A significant correlation between IL-12Rβ2 and IL-23R expression was identified overall in the LC tissues, particularly among welldifferentiated LCs. Furthermore, patients with high tumor cell IL-12Rβ2 expression and low IL-23R expression had a higher survival rate than patients with low IL-12Rβ2 and high IL23Rexpression or high or low expression of both IL-12Rβ2 and IL-23R. Similar comparison did for IL-12Rβ2
+ TIL ratio and IL-23R + TIL ratio in LC tissues. In addition, similar correlations between IL-12Rβ2 and IL-23R positive ratios were identified, which were significant in welldifferentiated LC. Moreover, patients with positive ratios of IL-12Rβ2 high and IL-23R low TILs had a higher survival rate than patients with positive ratios of IL-12Rβ2 low and IL-23R high TILs or positive ratios of either IL-12Rβ2 low and IL-23R low or IL-12Rβ2 high and IL-23R high TILs. A favorable prognosis was associated with WD LC in which cancer cells were immunolabeled with high IL-12Rβ2 and low IL-23R expression. A cancer cell differentiation (histological grade) value for prognosis has been identified in breast cancer; however, a similar value in LC has not been fully clarified due to the following three factors: the confounded etiology; the variable TNM staging; and the limited morphological criteria [40] . In our study, we separated 61 patients into groups with WD or MPD tumors. According to the classification criteria, the WD tissues possessed well-defined borders, single mitoses, few enlarged nuclei and a high level of keratin [40] . These WD cancer cells were also characterized by high IL-12Rβ2 and low IL-23R expression. While the IL-23/IL-23R axis transcriptionally activates the STAT3 gene, which can further promote tumor cell proliferation [13, 19] , the IL-12/IL-12Rβ2 axis mediates STAT4 activation in opposing regulation of the tumor cells [41] . In vivo, IL-12Rβ2 + B16 melanoma clones showed significantly inhibited tumorigenicity compared with IL-12Rβ2 − clones in IL-12Rβ2-KO mice, while IL-23R-KO mice also demonstrated inhibited tumorigenicity for both B16F10 melanoma and LL2 lung carcinoma [13] . These results indicate that intrinsic equilibrium between IL-12Rβ2 and IL-23R and the mechanisms for maintaining that equilibrium are associated with tumor cell differentiation and tumor invasion. Here, we observed a significant correlation between IL-12Rβ2 and IL-23R expression in WD cancer cells, whereas a similar significant correlation was not observed in MPD tumors. This result may indicate that IL-12Rβ2 and IL-23R have opposing roles in tumor progression and thereby create an immune-mediated equilibrium in WD cancer cells, whereas MPD tumors had lost that equilibrium, leading to aggressive invasiveness and an unfavorable prognosis.
TILs exert both host-protecting and tumor-sculpting effects on tumorigenesis, and the opposing roles of IL-12Rβ2 + and IL-23R + TILs create a homeostasis (balanced equilibrium) that is associated with good prognosis. Expression of both IL-12Rβ2 and IL-23R are highly regulated on T cells as contributors to a Th cell phenotype commitment [17] . Specifically, IFN-γ antagonizes TGFβ and IL-6 in naïve CD4+ T cell plasticity as follows: IFN-γ stimulates transcription factor T-bet expression, and upregulated T-bet in turn can promote IL-12Rβ2 expression and thereby maintain the Th1 cell phenotype to perform the host-protecting role via STAT4-IFN-γ activation. In contrast, TGFβ and IL-6 promote Th17 cell differentiation via IL-23R upregulation and STAT3 activation and differentiated CD4 + Th17 cells in turn can secrete IL-17 to further enhance the tumor-sculpting role [13, 14, 17] . Therefore, opposing roles of IL-12Rβ2 + and IL-23R + TILs create a homeostasis (balanced equilibrium). In our studies, we found that in WD cancer cells, a high ratio of IL-12Rβ2 + and low ratio of IL-23R + TILs was associated with a favorable prognosis. However, MPD cancer cells had lost that homeostasis and thus exhibited an unfavorable prognosis. This result suggests that homeostasis is associated with a favorable prognosis in LC cancer.
Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry
In the tumor microenvironment, low oxygen tension (hypoxia) may disrupt the homeostasis of IL-12Rβ2 and IL-23R in cancer cells and in TILs via blocking tumor cell differentiation or the TIL lineage. Solid tumors constantly manifest hypoxia, and hypoxic tumors appear to be PD [42] . In addition, the cause of the poor differentiation is that the hypoxia niche can maintain undifferentiated states of CSCs and TIL naïve phenotypes via enhanced EMT for cancer stem cells or blocked commitment for the IL-12Rβ2 + TIL lineage [43, 44] . PD cancer cells exhibit accelerated tumor growth and consume more oxygen; this increased oxygen consumption devastates the tumor hypoxic microenvironment and thereby causes necrosis at the tumor center [43] . In our study, we found that PD tumors were consistently accompanied by necrosis, where the viable tumor cells had low IL-12Rβ2 expression and very low ratios of IL-12Rβ2 + TILs (Fig. 4) . Therefore, this phenomenon indicates that hypoxia is associated with low IL-12Rβ2expression within both tumor cells and TILs; however, the intrinsic mechanism by which hypoxia downregulates IL-12Rβ2 expression remains largely unknown and requires further research.
In previous studies, the opposing roles of IL-12Rβ2 and IL-23R were shown to be regulated by epigenetic modifications in which silencing IL-12Rβ2 and/or activating IL-23R served as potential mechanisms for cancer cell immunoediting [6, 7] and TIL plasticity [45] . IL-12Rβ2 and IL-23R epigenetic modifications mainly included CpG island methylation and histone post-translation modification [45] [46] [47] [48] [49] . In human lung cancer cells, IL-23R was shown to be upregulated via the TGFβ1 signaling pathway, while aberrant methylation could silence IL-12Rβ2 and IL-12Rβ2, which serve as a potential prognostic factor for lung adenocarcinoma [32] . Furthermore, in pediatric B-acute lymphoblastic leukemia cells, exon 1 methylation of IL-12Rβ2gene can also silence IL-12Rβ2, which is a cancer cell immunoediting mechanism [49] . Moreover, for CD4 + Th1/Th17 TIL plasticity, T-bet activation was crucial and essential, and T-bet was regulated by histone post-translational modification [45, 46] . H3K4me3 was associated with T-bet activation, while H3K27me3 was associated with T-bet silencing. When the same regions were modified by both H3K4me3 and H3K27me3, the co-localized DNA modification region was called the 'bivalent' domain. The T-bet region, as one vital bivalent domain, can be activated by removal of the H3K27me3 suppressive effect and can thereby promote Th1 cell plasticity through elevated IL-12Rβ2 expression. In contrast, upregulated IL-23R expression is associated with Th17 cell plasticity with maintenance of the H3K27me3 effect by TGF-β1 [45, 47] . However, the precise role of IL-23 on Th17 cell plasticity remains unclear and requires further research within the tumor microenvironment.
Many in vivo and in vitro studies have identified the opposing roles of IL-12Rβ2 and IL-23R within the tumor microenvironment on tumor cells and TILs; furthermore, hypoxia and tumorigenesis may genetically and epigenetically regulate tumor cell differentiation and TIL plasticity, which may further impact immunoediting CSCs and promote tumor evasion and metastasis [45, 49] . However, the intrinsic mechanisms through which genetic and epigenetic modification affect the homeostasis of IL-12Rβ2 and IL-23R and their impact on tumor cell immunoediting remain largely unknown due to methodological limitation [32] . Furthermore, many studies have focused on specific positive ratios of lymphocyte subtypes and their hazard ratios for prognosis, but there was high variability in the density and quantity of intra-tumor or peripheral-tumor TILs with dynamic alterations within the hypoxic niches (including necrosis) [34] . This variety causes difficulty in IL-12Rβ2 + and IL-23R + TIL calculations. Furthermore, semi-quantitative analysis of tumor cell expression of IL-12Rβ2and IL-23R via IHC method cannot precisely evaluate the dynamic shifting phases of elimination, equilibrium and escape during tumor immunoediting [5, 7] . In addition, our limited sample size may cause a possible selection bias that could confound the results of this study; thus, further well-designed larger studies are required to validate our findings. 
Conclusion
Taken together, our results suggest that IL-12Rβ2 and IL-23R create a homeostasis in the tumor cells and TILs, and this homeostasis associated with good prognosis. High IL-12Rβ2 expression and low IL-23R expression were associated with WD tumors and less hypoxia within the tumor microenvironment, and thereby indicated a favorable prognosis. Likewise, tumors associated with positive ratios of high IL-12Rβ2 and low IL-23R TILs were also associated with a higher degree of differentiation and less hypoxia and indicated a favorable prognosis. However, the intrinsic mechanisms of epigenetic immunoediting for IL-12Rβ2 and IL-23R remain largely unknown. To confirm our findings and elucidate the underlying mechanisms, additional larger population or functional studies are warranted for validation. 
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